Mp26-12 Citralith™ Powder Supplement as a Treatment for Hypocitraturia in Patients With Nephrolithiasis

You have accessJournal of UrologyStone Disease: Medical & Dietary Therapy (MP26)1 May 2024MP26-12 CITRALITH™ POWDER SUPPLEMENT AS A TREATMENT FOR HYPOCITRATURIA IN PATIENTS WITH NEPHROLITHIASIS Eric Wang, Jennifer Y. Lu, Kelley Zhao, Kerry Adler, Scott Herfel, Yefim R. Sheynkin, and David Schulsinger Eric WangEric Wang , Jennifer Y. LuJennifer Y. Lu , Kelley ZhaoKelley Zhao , Kerry AdlerKerry Adler , Scott HerfelScott Herfel , Yefim R. SheynkinYefim R. Sheynkin , and David SchulsingerDavid Schulsinger View All Author Informationhttps://doi.org/10.1097/01.JU.0001009408.66023.77.12AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Potassium citrate is commonly given to stone-forming patients to alkalinize urine and increase urinary citrate levels because both hypocitraturia and low urine pH are associated with calcium oxalate stones. Potassium citrate is often recommended to patients to increase urine pH and increase urinary citrate to levels above the normal threshold (>550 mg/L for females, >450 mg/L for males). However, these supplements can be difficult to take due to large size of tablet or poor taste. This study aims to investigate the efficacy and tolerability of CitraLith™, a powder supplement containing potassium citrate, magnesium citrate and sodium citrate. METHODS: A retrospective study of patients who were started on CitraLith™ between April 2022 and April 2023 at a single institution was conducted. Only patients with known history of calcium oxalate stones and hypocitraturia proven by 24-hour urine studies were included. Using univariate analysis, results of 24-hour urine studies collected before CitraLith™ initiation were compared against those collected >3 months after initiation. Patients were also surveyed about user experience. RESULTS: 15 patients (8 females, 7 males) with a mean age 60.7 years. There was a significant difference between mean urinary citrate levels prior to starting CitraLith™ of 310.9 mg/L and follow-up urinary citrate level at 3-6 months of 586.3 mg/L (p=0.001). Urinary magnesium level was also significantly improved from 104.6 mg/L pre-supplement to 150.5 mg/L post-supplement (p=0.003). There was no significant change in total urine output or urinary pH, sodium, or oxalate. All subjects tolerated the supplement well, and none discontinued its use. When asked about their experiences using the supplement, 73% of respondents felt the supplement was easy to ingest and found the taste of the supplement acceptable. The most common complaints were a slight metallic taste and occasional difficulty in dissolving the supplement in water. CONCLUSIONS: CitraLith™ significantly increased 24-hour urine citrate and magnesium concentrations in this cohort. CitraLith™ was well tolerated, effective and could potentially be safely offered as an alternative to those unwilling or unable to take other citrate supplements. Source of Funding: The authors have no sources of funding to disclose © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e418 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Eric Wang More articles by this author Jennifer Y. Lu More articles by this author Kelley Zhao More articles by this author Kerry Adler More articles by this author Scott Herfel More articles by this author Yefim R. Sheynkin More articles by this author David Schulsinger More articles by this author Expand All Advertisement PDF downloadLoading ...